Does valganciclovir have a role in glioblastoma therapy?

Neuro-Oncology

Volumn 16, Issue 3, 2014, Pages 330-331

  Cobbs, Charles S ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; GLIOBLASTOMA; HUMANS;

EID: 84894224969     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou009     Document Type: Short Survey

References (17)

1. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347-3350.
2. Cobbs CS. Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects. Curr Opin Oncol. 2013;25(6):682-688.
3. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012; 14(3):246-255.
4. Matlaf LA, Harkins LE, Bezrookove V, et al. Cytomegalovirus pp71 protein is expressed in human glioblastoma and promotes pro-angiogenic signaling by activation of stem cell factor. PLoS One. 2013;8(7):e68176.
5. Soroceanu L, Matlaf L, Bezrookove V, et al. Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res. 2011;71(21):6643-6653.
6. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factoralpha receptor activation is required for human cytomegalovirus infection. Nature. 2008;455(7211):391-395.
7. Cobbs CS, Soroceanu L, Denham S, et al. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 2008;68(3):724-730.
8. Straat K, Liu C, Rahbar A, et al. Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst. 2009;101(7):488-497.
9. Dziurzynski K, Wei J, Qiao W, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011;17(14): 4642-4649.
10. Pari GS, Netski D, St Jeor S, et al. Generation of a nude mouse tumor model for in vivo replication of human cytomegalovirus. J Infect Dis. 1998;177(3):523-528.
11. Baryawno N, Rahbar A,Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121(10):4043-4055.
12. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer. 2013;133(5):1204-1213.
13. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013; 369(10):985-986.
14. Hadaczek P, Ozawa T, Soroceanu L, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013;19(23):6473-6483.
15. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 2008;10(1):10-18.
16. Dos Santos CJ, Stangherlin LM, Figueiredo EG, et al. High prevalence of HCMV and viral load in tumor tissues and peripheral blood of glioblastoma multiforme patients [published online ahead of print October 30, 2013]. J Med Virol. 2013. doi:10.1002/jmv.23820.
17. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300(4):413-422.